Hypercholesterolemic effect of drug-type Cannabis sativa L. seed (marijuana seed) in guinea pig

Pakistan Journal of Nutrition

Volumn 6, Issue 1, 2007, Pages 59-62

  Hayatghaibi, Hossein ^a   Karimi, Isaac ^b  

^a Islamic Azad Veterinary School   (Iran)

^b URMIA UNIVERSITY   (Iran)

Author keywords

Guinea pig; Hypercholesterolemia; Lipid profile; Marijuana; Tetrahydrocannabinol

Indexed keywords

CANNABIS; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KETAMINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PROTEIN; SATURATED FATTY ACID; TRIACYLGLYCEROL; UNSATURATED FATTY ACID; XYLAZINE;

ANIMAL EXPERIMENT; ANIMAL FOOD; ARTICLE; ATHEROSCLEROSIS; AUTOANALYZER; CARDIOVASCULAR DISEASE; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; DIET RESTRICTION; FOOD PROCESSING; GUINEA PIG; HEMATOLOGICAL PARAMETERS; HYPERCHOLESTEROLEMIA; NONHUMAN; NUTRITION; PLANT SEED;

ANIMALIA; CANNABIS; CANNABIS SATIVA; CAVIA;

EID: 33846270017     PISSN: 16805194     EISSN: None     Source Type: Journal    
DOI: 10.3923/pjn.2007.59.62     Document Type: Article

References (38)

1. Adams, I.B. and B.R. Martin, 1996a. Cannabis: pharmacology and toxicology in animals and humans. Addiction., 91: 1585-1614.
2. Adams, I.B. and B.R. Martin, 1996b. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol. Therap., 95: 185-190.
3. Arnone, M., J. Maruani, F. Chaperon, M.H. Thiebot, M. Poncelet, P. Soubrie and G. Le Fur, 1997. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology, 132: 104-106.
4. Breivogel, C.S. and S.R. Childers, 1998. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis., 5: 417-431.
5. Brousseau, M.E. and E.J. Schaefer, 2000. Diet and Coronary Heart Disease: Clinical Trials.Curr. Atheroscler. Rep., 2: 487-493.
6. Callaway, J.C., 2004. Hempseed as an nutritional resource: An review. Euphytica., 14: 65-72.
7. Callaway, J.C., L.K. Summers., H. Bradshaw and K.N. Frayn, 2002.Changes in LDL particle composition after the consumption of meals containing different amounts and types of fat. Am. J. Clin. Nutr., 76: 345-350.
8. Colombo, G., R. Agabio, G. Diaz, C. Lobina, R. Reali and G.L. Gessa, 1998. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life. Sci., 63: PL113-PL117.
9. Darshan, S.K. and I.L. Rudolph, 2000. Effect of fatty acids of w-6 and w-3 type on human immune status and role of eicosanoids. Nutr., 16:143-145.
10. Devane, W.A. and R. Mechoulam, 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptors. Science., 258:1946-1949.
11. Di Marzo, V., S.K. Goparaju, L. Wang, J. Liu, S. Batkai, Z. Jarai, F. Fezza, G.I. Miura, R.D. Palmiter, T. Sugiura and G. Kunos, 2001. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature., 410: 822-825.
12. Elliot, M.B. and R. Mechoulam, 2002. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol. Therap., 95: 185-190.
13. Evans, M. and A. Rees, 2002. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?. Drug. Saf., 25: 649-663.
14. Farmer, J.A., 2003. Statins and myotoxicity. Curr. Atheroscler. Rep., 5: 96-100.
15. Fernandez, M.L. and D.J. McNamara, 1991.Regulation of cholesterol and lipoprotein metabolism in guinea pigs mediated by dietary fat quality and quantity. J. Nutr., 121: 934-943.
16. Gordon, T., W.P. Castelli, M.C. Hjotland, W.B. Kannel and T.R. Dawber, 1997. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med., 62: 707-714.
17. Goutopoulos, A. and A. Makriyannis, 2002. From cannabis to cannabinergics:new therapeutic opportunities. Pharmacol. Therap., 95: 103-117.
18. Grundy. S.M., J.I. Cleeman, C.N. Merz. H.B. Brewer. L.T. Clark, D.B. Hunninghake, R.C. Pastemak, S.C. Smith and N.J. Stone, 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation., 110: 227-239.
19. Karimi, I. and H. Hayatghaibi, 2006. Effect of Cannabis sativa L. Seed (Hempseed) on Lipid and Protein Profiles of Rat. Pak. J. Nutr., 5: 585-588.
20. Katan, M.B., S.M. Grundy, P. Jones, M. Law, T. Miettinen and R. Paoletti, 2003. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo. Clin. Proc., 78: 965-978.
21. Kawahiri, M., C. Maugeais and D. Rader, 2000. High-density lipoprotein metabolism: Molecular target for new therapies for atherosclerosis. Curr. Atherosclerosis. Rep., 2: 363-372.
22. Keys, A., 1997. Coronary heart disease in seven countries. Nutrition., 13: 250-252.
23. Kirkham, T.C. and M.C. Williams, 2001. Endogenous cannabinoids and appetite. Nutr. Res. Rev., 14: 65-86.
24. Koch, J.E., 2001. Delta 9-THC stimulates food intake in Lewis rats: effects on chow, high-fat, and sweet high-fat diets. Pharmacol. Biochem. Behav., 68: 539-543.
25. Leizer, C., D. Ribnicky, A. Poulev, S. Dushenkov and I. Raskin, 2000. The composition of hempseed oil and its potential as an important source of nutrition. J. Nutr. Fun. Med. Food., 2: 35-53.
26. Malini, T. and G. Vanithakumari, 1990. Rat toxicity studies with b-sitosterol. Ethnopharmacology., 28: 221-234.
27. Mensink, R.P., P.L. Zock, A.D. Kester and M.B. Katan, 2003. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am. J. Clin., 77: 1146-1155.
28. O'Keefe, J.H., L. Cordian, W.H. Harris, R.M. Moe and R. Vogel, 2004. Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal. J. Am. Coll. Cardiol., 43: 2142-2146.
29. Ostlund, R.E., 2004. Phytosterols and cholesterol metabolism. Curr. Opin. Lipidol., 15: 37-41.
30. Paul, E., P.E. Szmitko and V. Subodh, 2006.Does cannabis hold the key to treating cardiometabolic disease? Nature. Clin. Pra. Cardio. Med., 3: 116-117.
31. 9-THC content of both drug- and fiber-type cannabis seeds. J. Anal. Toxicol., 24: 715-717.
32. Simiand, J., M. Keane, P.E. Keane and P. Soubrié, 1998. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol., 9: 179-181.
33. Small, E. and D. Marcus, 2003. Tetrahydrocannabinol levels in hemp (Cannabis sativa) germplasm resources. Econ. Bot., 57: 545-558.
34. Stein, E.A., 2003. The power of statins: aggressive lipid lowering. Clin. Cardiol., 26: III25-III31.
35. Tavazzi, L., 1999. Clinical epidemiology of acute myocardial infarction. Am. Heart. J., 138: S48-S54.
36. Van Gaal, L., 2004. The RIO-Europe Study: Use of a Selective CB1 Receptor Blocker (Rimonabant) in the Management of Obesity and Related Metabolic Risk Factors. ESC Abstract.
37. Verty, A., I.S. McGregor and P.E. Mallet, 2004. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci. Lett., 354: 217-220.
38. 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol. Biochem. Behav., 71:341-348.